ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bupropion

Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.

Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.

Drug pageBupropion: every studyMany companies study it; this page follows only the 19 they lead. All 217 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 24, 200219 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only80 open or runningphase 3since Sep 24, 2002Sep 24, 2002none ahead
Teva Pharmaceutical Industriesits history only60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Rose Research Centerits history only20 open or runningphase 3since May 11, 2020May 11, 2020none ahead
Johnson & Johnsonits history only10 open or runningphase 1since Oct 2, 2015Oct 2, 2015none ahead
Novartisits history only10 open or runningphase 1since Apr 16, 2009Apr 16, 2009none ahead
Takeda10 open or runningphase 4since Nov 24, 2015Nov 24, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 24, 2015First study: phase 4 study in Weight Regain Post Bariatric SurgeryFirst studyNCT02616315 · United States

TargetBeta

“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
dexmethylphenidaterulecingulate-therapeuticsphase 414
AmphetamineruleTris Pharmaphase 48

Studies

The one study Takeda leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02616315Weight Regain Post Bariatric Surgery · United States4WithdrawnOct 20170

How it is read

Names in the registry

  • “Bupropion”, 7 entries
  • “bupropion hydrochloride”, 3 entries
  • “Extended-release Bupropion Hydrochloride”, 2 entries
  • “Extended-release bupropion hydrochloride”, 2 entries
  • “Bupropion HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.